Gastrointestinal carcinoma affects organs along the digestive tract, from the esophagus to the colon and rectum. Treatment aims to control the disease, ease symptoms, and improve quality of life—and approaches vary widely depending on where the cancer is located and how advanced it has become.

Fighting Cancer Along the Digestive Pathway

When cancer develops anywhere in the gastrointestinal tract—the 25-foot-long pathway that processes everything we eat—treatment must be carefully tailored to the tumor’s location, size, and stage. The goal of therapy is not just to remove or shrink cancer, but to help patients maintain nutrition, manage pain, and preserve their ability to live as fully as possible^[1].

Treatment decisions depend heavily on how far the cancer has spread. For cancers caught early, surgery combined with chemotherapy or radiation can often eliminate the disease. For advanced cases where cancer has reached other organs, the focus shifts to slowing progression, controlling symptoms, and supporting the patient through every phase of care^[2].

Standard treatments approved by medical societies form the backbone of care. These include surgery to remove tumors, chemotherapy drugs that kill rapidly dividing cells, and radiation that targets cancerous tissue. But the landscape is changing. Researchers are now testing innovative therapies in clinical trials, including drugs that harness the immune system and molecules designed to attack specific cancer pathways^[1][11].

Proven Therapies for Gastrointestinal Cancer

Surgery remains one of the most effective treatments when the tumor is localized and can be safely removed. The type of operation depends on where the cancer sits. For example, if cancer forms in the stomach, doctors may perform a gastrectomy, removing part or all of the stomach depending on tumor size and location. A subtotal gastrectomy takes out the cancerous portion along with nearby lymph nodes, while a total gastrectomy removes the entire stomach and reconnects the esophagus directly to the small intestine so the patient can still eat and swallow^[12].

For colorectal cancers—the most common type of gastrointestinal cancer in the United States—surgery may involve removing sections of the colon or rectum. In some cases, doctors place a stent, a small expandable tube, to keep a blocked passage open so food and waste can move through the digestive system^[12].

Chemotherapy is often given before surgery to shrink tumors, making them easier to remove. This is called neoadjuvant therapy. After surgery, chemotherapy may continue as adjuvant therapy to kill any remaining cancer cells and reduce the chance of the disease returning. Chemotherapy drugs circulate through the bloodstream, reaching cancer cells throughout the body. However, they also affect healthy cells, which can lead to side effects like fatigue, nausea, hair loss, and changes in appetite^[11][12].

The specific drugs used depend on the type and stage of cancer. For stomach cancer, doctors often use combinations of three chemotherapy agents—called triplet chemotherapy—which has become a widely accepted standard for resectable disease. Treatment typically continues for several months, with patients receiving infusions every two weeks^[14].

Radiation therapy uses high-energy beams to destroy cancer cells in a specific area. It’s frequently combined with chemotherapy, a combination known as chemoradiation. This approach is common for cancers of the esophagus and stomach, where radiation can shrink tumors before surgery or help relieve symptoms in advanced disease. External radiation therapy, where a machine directs beams at the tumor from outside the body, is the most common form used for gastrointestinal cancers^[12].

Clinical guidelines from medical societies help doctors decide which treatments to use and in what order. For example, patients with locally advanced stomach cancer often receive chemotherapy first, then surgery, followed by more chemotherapy. The entire treatment course can span six months or longer. Regular imaging scans—typically every two to three months—track how well the cancer is responding^[14].

Side effects from standard treatments vary. Chemotherapy can cause low white blood cell counts, increasing infection risk. It may also lead to neuropathy, a tingling or numbness in the hands and feet caused by nerve damage. Radiation can irritate the esophagus, causing painful swallowing, or lead to skin changes in the treated area. Surgical side effects depend on the extent of the operation but can include difficulty eating, changes in bowel habits, and the need for nutritional support^[11][12].

Exploring New Frontiers in Clinical Trials

While standard treatments have saved countless lives, researchers continue searching for better options. Clinical trials test new drugs and approaches that may one day become standard care. These trials move through phases, each designed to answer specific questions about safety and effectiveness.

Phase I trials focus on safety. Researchers carefully test a new drug or therapy on a small group of people to find the right dose and identify side effects. Phase I studies help determine whether a treatment is safe enough to test further^[12].

Phase II trials expand the group and measure whether the treatment actually works against cancer. Do tumors shrink? Do symptoms improve? These studies provide the first real evidence of effectiveness. If results are promising, the treatment advances to Phase III^[12].

Phase III trials compare the new treatment to the current standard. Hundreds or even thousands of patients participate. Only treatments that prove superior or equally effective with fewer side effects move forward to approval by regulatory agencies like the U.S. Food and Drug Administration.

For gastrointestinal cancers, several types of experimental therapies are showing promise in clinical trials. Immunotherapy drugs work by helping the immune system recognize and attack cancer cells. One group of immunotherapy drugs called checkpoint inhibitors targets proteins like PD-1 and PD-L1. These proteins act like brakes on immune cells. Cancer cells sometimes use these brakes to hide from the immune system. Checkpoint inhibitors release the brakes, allowing immune cells to fight the cancer^[15].

Several checkpoint inhibitors have been approved for certain patients with advanced stomach or gastroesophageal cancer. Pembrolizumab and nivolumab are two examples. These drugs target the PD-1/PD-L1 pathway and are particularly effective in tumors with certain characteristics. For instance, cancers with microsatellite instability (MSI) or high tumor mutation burden (TMB) respond better to immunotherapy. Tumors positive for the Epstein-Barr virus also show stronger responses^[14][15].

Another immunotherapy drug, dostarlimab, has been approved for patients whose tumors have DNA mismatch repair deficiency. This condition makes tumors more vulnerable to immune attack. Early results from clinical trials show that some patients experience significant tumor shrinkage and improved survival^[15].

Targeted therapy drugs attack specific molecules involved in cancer growth. Unlike chemotherapy, which affects all rapidly dividing cells, targeted drugs zero in on particular pathways. For stomach cancers that produce too much of a protein called HER2, drugs like trastuzumab can block this protein’s signals. Trastuzumab is a monoclonal antibody that attaches to HER2 receptors on cancer cells, preventing them from receiving growth signals^[15].

A newer version, trastuzumab deruxtecan, combines the targeted antibody with a chemotherapy drug. This antibody-drug conjugate delivers chemotherapy directly to cancer cells, sparing more healthy tissue. Clinical trials have shown improved outcomes in patients with HER2-positive gastroesophageal cancer who received this treatment^[15].

Ramucirumab is another targeted drug that blocks blood vessel growth around tumors. Cancer needs a blood supply to grow and spread. By targeting the VEGF/VEGFR2 pathway, ramucirumab can slow or stop tumor growth. It’s approved for certain patients with advanced stomach or gastroesophageal cancer^[15].

Researchers are also investigating CAR T cell therapy, a treatment that involves removing a patient’s immune cells, modifying them in a laboratory to better recognize cancer, and then infusing them back into the body. This approach has shown remarkable success in blood cancers and is now being tested for solid tumors, including those of the gastrointestinal tract^[15].

Clinical trials for gastrointestinal cancers are conducted around the world, including in the United States, Europe, and other regions. Eligibility depends on many factors: the type and stage of cancer, previous treatments, overall health, and whether the tumor has specific molecular markers. Patients interested in clinical trials should discuss options with their oncologist, who can help determine which trials might be suitable^[1].

Some trials test treatments that target specific genetic mutations found in a patient’s tumor through molecular profiling. This approach, sometimes called precision medicine, matches patients to therapies based on their tumor’s unique characteristics rather than just its location in the body. For gastrointestinal cancers, researchers are exploring therapies that target pathways involved in cell growth, inflammation, and blood vessel formation^[14].

Another experimental approach is hyperthermic intraperitoneal chemotherapy (HIPEC). During surgery to remove visible tumors, doctors deliver heated chemotherapy directly into the abdominal cavity. The heat helps the drugs penetrate deeper into tissues, killing microscopic cancer cells that surgery cannot reach. HIPEC is being studied for advanced gastrointestinal cancers that have spread within the abdomen^[12].

Most common treatment methods

• Surgery
  • Subtotal gastrectomy removes part of the stomach, nearby lymph nodes, and surrounding tissues
  • Total gastrectomy removes the entire stomach and reconnects the esophagus to the small intestine
  • Endoluminal stent placement uses a thin expandable tube to open blocked passages
  • Gastrojejunostomy removes the cancerous part of the stomach blocking the small intestine and connects the stomach to the jejunum
• Chemotherapy
  • Neoadjuvant chemotherapy given before surgery to shrink tumors
  • Adjuvant chemotherapy given after surgery to kill remaining cancer cells
  • Triplet chemotherapy uses three drugs together and is standard for resectable gastric cancer
  • Treatment typically continues for several months with infusions every two weeks
• Radiation therapy
  • External radiation therapy directs high-energy beams at the tumor from outside the body
  • Often combined with chemotherapy (chemoradiation) to improve effectiveness
  • Used before surgery to shrink tumors or to relieve symptoms in advanced disease
• Immunotherapy
  • Pembrolizumab and nivolumab are checkpoint inhibitors targeting the PD-1/PD-L1 pathway
  • Dostarlimab approved for tumors with DNA mismatch repair deficiency
  • Most effective in tumors with microsatellite instability, high tumor mutation burden, or Epstein-Barr virus positivity
• Targeted therapy
  • Trastuzumab blocks HER2 protein signals in HER2-positive cancers
  • Trastuzumab deruxtecan combines a targeted antibody with chemotherapy
  • Ramucirumab blocks blood vessel growth by targeting the VEGF/VEGFR2 pathway
• Endoscopic procedures
  • Endoscopic mucosal resection removes early-stage cancer from the digestive tract lining using an endoscope
  • Endoluminal laser therapy uses a laser attached to an endoscope to open blockages
• Hyperthermic intraperitoneal chemotherapy (HIPEC)
  • Heated chemotherapy delivered directly into the abdominal cavity during surgery
  • Being studied for advanced cancers that have spread within the abdomen

Living with Treatment and Its Challenges

Treatment for gastrointestinal cancer affects more than just the tumor. Surgery that removes part or all of the stomach changes how the body processes food. Patients often need to eat smaller, more frequent meals—sometimes six to eight times a day instead of three. Staying upright after eating can help prevent discomfort. A registered dietitian can provide essential guidance on maintaining proper nutrition and managing weight loss, which is common during and after treatment^[21].

One challenge many patients face is dumping syndrome, which happens when food moves too quickly from the stomach into the small intestine. This can cause nausea, cramping, diarrhea, and sweating after eating. Dietary changes—such as eating slowly, avoiding sugary foods, and separating liquids from solids during meals—can help manage these symptoms^[21].

Advanced cancer can cause ongoing fatigue, pain, and difficulty eating. Palliative care specialists work alongside oncologists to manage these symptoms. They focus on improving quality of life through pain control, nutritional support, and emotional counseling. Palliative care is not the same as hospice; it can be provided at any stage of illness, even while receiving active treatment^[19].

Follow-up care after treatment involves regular visits to the doctor for physical exams and imaging scans. These appointments monitor for signs of cancer returning and manage any long-term side effects. The frequency of follow-up visits depends on the type and stage of cancer but typically occurs every few months initially, then less often over time^[23].

Emotional support is equally important. A cancer diagnosis affects mental health, relationships, and daily routines. Many patients benefit from support groups where they can connect with others facing similar challenges. Counseling services, either individual or family-based, help patients and loved ones cope with fear, anxiety, and uncertainty^[20].